Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Research analysts at B. Riley issued their Q3 2025 EPS estimates for shares of Axsome Therapeutics in a note issued to investors on Tuesday, September 30th. B. Riley also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($4.07) EPS, FY2026 earnings at $0.60 EPS, FY2027 earnings at $8.00 EPS, FY2028 earnings at $17.66 EPS and FY2029 earnings at $24.58 EPS. Get Axsome Therapeutics alerts:Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its quarterly earnings results on Monday, August 4th. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%. Featured ArticlesReceive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.